4 March 2015, 10:40 am
Smoking appears to contribute most to the burden of non-AIDS-defining cancers diagnosed in people living with HIV in the US, out of all the potential modifiable risk factors – including hepatitis B or C, low CD4 cell count, an AIDS diagnosis or having an unsuppressed viral load – according to a study reported last


4 March 2015, 9:30 am
The smoking cessation drug varenicline (Champix, or Chantix in the United States) helped more people with HIV to stop smoking than counselling alone, but less than 20% were able to remain abstinent for a year, according to the results of a French study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2015)


4 March 2015, 7:50 am
Bristol-Myers Squibb's BMS-663068 or fostemsavir, a first-in-class HIV attachment inhibitor that stops the virus from binding to and entering cells, was well-tolerated and demonstrated good antiviral activity in a study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2015) last week in Seattle, USA. Related research showed that BMS-663068 can safely be


3 March 2015, 12:20 pm
People with HIV and hepatitis C co-infection who delay hepatitis C treatment remain at risk for liver failure, hepatocellular carcinoma and liver-related death even after being cured – with outcomes worsening the longer it is put off – indicating that treatment should not be deferred until advanced disease, according to a presentation at


3 March 2015, 12:10 pm
The burden of hepatitis C virus (HCV) infection is high in the US, with a substantial number of individuals born between 1945 and 1965 having advanced liver fibrosis or cirrhosis and therefore being at high priority for treatment, according to a report presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2015) last week


1 2
LATEST VIDEOS

TAKE ACTION
UPCOMING EVENTS
    • No upcoming events
  • YOUR NEWS
  • View All Add your news
    YOUR PICTURES
  • LATEST TWEETS